{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:42:22Z","timestamp":1789501342294,"version":"build-2803163510"},"publisher-location":"Cham","reference-count":33,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031121838","type":"print"},{"value":"9783031121845","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/7854_2021_279","type":"book-chapter","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T09:50:22Z","timestamp":1642153822000},"page":"247-259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Psilocybin for the Treatment of Obsessive-Compulsive Disorders"],"prefix":"10.1007","author":[{"given":"Katja","family":"Ehrmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. B.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco A.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"issue":"1","key":"279_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/nyas.12360","volume":"1316","author":"JR Andrews-Hanna","year":"2014","unstructured":"Andrews-Hanna JR, Smallwood J, Spreng RN (2014) The default network and self-generated thought: component processes, dynamic control, and clinical relevance. Ann N Y Acad Sci 1316(1):29","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"279_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/YCO.0000000000000467","volume":"32","author":"RL Carhart-Harris","year":"2019","unstructured":"Carhart-Harris RL (2019) How do psychedelics work? Curr Opin Psychiatry 32(1):16\u201321","journal-title":"Curr Opin Psychiatry"},{"issue":"3","key":"279_CR3","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1124\/pr.118.017160","volume":"71","author":"RL Carhart-Harris","year":"2019","unstructured":"Carhart-Harris RL, Friston KJ (2019) REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacol Rev 71(3):316\u2013344","journal-title":"Pharmacol Rev"},{"issue":"9","key":"279_CR4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1177\/0269881117725915","volume":"31","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris RL, Nutt DJ (2017) Serotonin and brain function: a tale of two receptors. J Psychopharmacol 31(9):1091\u20131120","journal-title":"J Psychopharmacol"},{"issue":"3","key":"279_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1176\/appi.psychotherapy.2009.63.3.245","volume":"63","author":"S Chlebowski","year":"2009","unstructured":"Chlebowski S, Gregory RJ (2009) Is a psychodynamic perspective relevant to the clinical management of obsessive\u2013compulsive disorder? Am J Psychother 63(3):245\u2013256","journal-title":"Am J Psychother"},{"issue":"4","key":"279_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/02791072.1998.10399711","volume":"30","author":"PL Delgado","year":"1998","unstructured":"Delgado PL, Moreno FA (1998) Hallucinogens, serotonin and obsessive-compulsive disorder. J Psychoactive Drugs 30(4):359\u2013366","journal-title":"J Psychoactive Drugs"},{"issue":"2","key":"279_CR7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.31887\/DCNS.2010.12.2\/efoa","volume":"12","author":"EB Foa","year":"2010","unstructured":"Foa EB (2010) Cognitive behavioral therapy of obsessive-compulsive disorder. Dialogues Clin Neurosci 12(2):199\u2013207","journal-title":"Dialogues Clin Neurosci"},{"issue":"5","key":"279_CR8","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0005-7894(78)80013-6","volume":"9","author":"EB Foa","year":"1978","unstructured":"Foa EB, Goldstein A (1978) Continuous exposure and complete response prevention in the treatment of obsessive-compulsive neurosis. Behav Ther 9(5):821\u2013829","journal-title":"Behav Ther"},{"key":"279_CR9","first-page":"421","volume-title":"Anxiety and the anxiety disorders","author":"EB Foa","year":"1985","unstructured":"Foa EB, Kozak MJ (1985) Treatment of anxiety disorders: implications for psychopathology. In: Tuma AH, Maser JD (eds) Anxiety and the anxiety disorders. Lawrence Erlbaum Associates, Hillsdale, pp 421\u2013452"},{"key":"279_CR10","first-page":"116","volume":"47","author":"A Freud","year":"1966","unstructured":"Freud A (1966) Obsessional neurosis: a summary of psycho-analytic views as presented at the congress. Int J Psychoanal 47:116\u2013122","journal-title":"Int J Psychoanal"},{"issue":"1","key":"279_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","volume":"7","author":"\u00d3F Gon\u00e7alves","year":"2017","unstructured":"Gon\u00e7alves \u00d3F, Soares JM, Carvalho S, Leite J, Ganho-\u00c1vila A, Fernandes-Gon\u00e7alves A, Pocinho F, Sampaio A (2017) Patterns of default mode network deactivation in obsessive compulsive disorder. Sci Rep 7(1):1\u20137","journal-title":"Sci Rep"},{"issue":"6","key":"279_CR12","doi-asserted-by":"publisher","first-page":"e1003664","DOI":"10.1371\/journal.pmed.1003664","volume":"18","author":"NP Gosmann","year":"2021","unstructured":"Gosmann NP, Costa MDA, Jaeger MDB, Motta LS, Frozi J, Spanemberg L, Manfro GG, Cuijpers P, Pine DS, Salum GA (2021) Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: a 3-level network meta-analysis. PLoS Med 18(6):e1003664","journal-title":"PLoS Med"},{"issue":"2","key":"279_CR13","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1080\/02791072.2020.1849879","volume":"53","author":"A Lugo-Radillo","year":"2021","unstructured":"Lugo-Radillo A, Cortes-Lopez JL (2021) Long-term amelioration of OCD symptoms in a patient with chronic consumption of psilocybin-containing mushrooms. J Psychoactive Drugs 53(2):146\u2013148","journal-title":"J Psychoactive Drugs"},{"key":"279_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.euroneuro.2020.02.001","volume":"33","author":"MK Madsen","year":"2020","unstructured":"Madsen MK, Fisher PM, Stenb\u00e6k DS, Kristiansen S, Burmester D, Lehel S, P\u00e1len\u00ed\u010dek T, Kucha\u0159 M, Svarer C, Ozenne B, Knudsen GM (2020) A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding. Eur Neuropsychopharmacol 33:71\u201380","journal-title":"Eur Neuropsychopharmacol"},{"issue":"13","key":"279_CR15","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1017\/S0033291721001744","volume":"51","author":"B Mahjani","year":"2021","unstructured":"Mahjani B, Bey K, Boberg J, Burton C (2021) Genetics of obsessive-compulsive disorder. Psychol Med 51(13):2247\u20132259","journal-title":"Psychol Med"},{"issue":"4","key":"279_CR16","first-page":"2","volume":"58","author":"JS March","year":"1997","unstructured":"March JS, Liebowitz M, Carpenter D, Kahn DA, Francis A (1997) The expert consensus guideline series: treatment of obsessive-compulsive disorder. J Clin Psychiatry 58(4):2\u201372","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"279_CR17","first-page":"1037","volume":"154","author":"FA Moreno","year":"1997","unstructured":"Moreno FA, Delgado PL (1997) Hallucinogen-induced relief of obsessions and compulsions. Am J Psychiatry 154(7):1037\u20131038","journal-title":"Am J Psychiatry"},{"issue":"11","key":"279_CR18","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","volume":"67","author":"FA Moreno","year":"2006","unstructured":"Moreno FA, Wiegand CB, Taitano EK, Delgado PL (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 67(11):1735\u20131740","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"279_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.neulet.2011.01.046","volume":"493","author":"JL Moreno","year":"2011","unstructured":"Moreno JL, Holloway T, Albizu L, Sealfon SC, Gonz\u00e1lez-Maeso J (2011) Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neurosci Lett 493(3):76\u201379","journal-title":"Neurosci Lett"},{"issue":"2","key":"279_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","volume":"101","author":"DE Nichols","year":"2004","unstructured":"Nichols DE (2004) Hallucinogens. Pharmacol Ther 101(2):131\u2013181","journal-title":"Pharmacol Ther"},{"key":"279_CR21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cpr.2015.06.003","volume":"40","author":"LG \u00d6st","year":"2015","unstructured":"\u00d6st LG, Havnen A, Hansen B, Kvale G (2015) Cognitive behavioral treatments of obsessive\u2013compulsive disorder. A systematic review and meta-analysis of studies published 1993\u20132014. Clin Psychol Rev 40:156\u2013169","journal-title":"Clin Psychol Rev"},{"issue":"3","key":"279_CR22","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.pharmthera.2011.09.006","volume":"132","author":"C Pittenger","year":"2011","unstructured":"Pittenger C, Bloch MH, Williams K (2011) Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther 132(3):314\u2013332","journal-title":"Pharmacol Ther"},{"issue":"4","key":"279_CR23","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.euroneuro.2016.01.005","volume":"26","author":"T Pokorny","year":"2016","unstructured":"Pokorny T, Preller KH, Kraehenmann R, Vollenweider FX (2016) Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A\/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur Neuropsychopharmacol 26(4):756\u2013766","journal-title":"Eur Neuropsychopharmacol"},{"key":"279_CR24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.psychres.2017.10.038","volume":"259","author":"AM Raines","year":"2018","unstructured":"Raines AM, Oglesby ME, Allan NP, Mathes BM, Sutton CA, Schmidt NB (2018) Examining the role of sex differences in obsessive-compulsive symptom dimensions. Psychiatry Res 259:265\u2013269","journal-title":"Psychiatry Res"},{"issue":"1","key":"279_CR25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-019-0102-3","volume":"5","author":"DJ Stein","year":"2019","unstructured":"Stein DJ, Costa D, Lochner C, Miguel EC, Reddy Y, Shavitt RG, van den Heuvel OA, Simpson HB (2019) Obsessive-compulsive disorder. Nat Rev Dis Primers 5(1):52","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"279_CR26","doi-asserted-by":"publisher","first-page":"e36356","DOI":"10.1371\/journal.pone.0036356","volume":"7","author":"ER Stern","year":"2012","unstructured":"Stern ER, Fitzgerald KD, Welsh RC, Abelson JL, Taylor SF (2012) Resting-state functional connectivity between fronto-parietal and default mode networks in obsessive-compulsive disorder. PLoS One 7(5):e36356","journal-title":"PLoS One"},{"key":"279_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.bbr.2016.07.004","volume":"313","author":"W Tang","year":"2013","unstructured":"Tang W, Zhu Q, Gong X, Zhu C, Wang Y, Chen S (2013) Cortico-striato-thalamo-cortical circuit abnormalities in obsessive-compulsive disorder: a voxel-based morphometric and fMRI study of the whole brain. Behav Brain Res 313:17\u201322","journal-title":"Behav Brain Res"},{"key":"279_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.psychres.2016.01.071","volume":"237","author":"S Taylor","year":"2016","unstructured":"Taylor S, Asmundson GJ, Jang KL (2016) Etiology of obsessions and compulsions: general and specific genetic and environmental factors. Psychiatry Res 237:17\u201321","journal-title":"Psychiatry Res"},{"issue":"8","key":"279_CR29","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1523\/JNEUROSCI.17-08-02785.1997","volume":"17","author":"VA Vaidya","year":"1997","unstructured":"Vaidya VA, Marek GJ, Aghajanian GK, Duman RS (1997) 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci 17(8):2785\u20132795","journal-title":"J Neurosci"},{"issue":"1","key":"279_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","volume":"7","author":"AL Van der Straten","year":"2017","unstructured":"Van der Straten AL, Denys D, Van Wingen GA (2017) Impact of treatment on resting cerebral blood flow and metabolism in obsessive compulsive disorder: a meta-analysis. Sci Rep 7(1):1\u20138","journal-title":"Sci Rep"},{"issue":"2","key":"279_CR31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.4088\/JCP.v66n0211","volume":"66","author":"NC Vulink","year":"2005","unstructured":"Vulink NC, Denys D, Westenberg HG (2005) Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed-dose study. J Clin Psychiatry 66(2):228\u2013230","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"279_CR32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/02791072.2014.963754","volume":"46","author":"JA Wilcox","year":"2014","unstructured":"Wilcox JA (2014) Psilocybin and obsessive compulsive disorder. J Psychoactive Drugs 46(5):393\u2013395","journal-title":"J Psychoactive Drugs"},{"key":"279_CR33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.neuropsychologia.2014.06.023","volume":"61","author":"L Zambrano-Vazquez","year":"2014","unstructured":"Zambrano-Vazquez L, Allen JJB (2014) Response monitoring in obsessive-compulsive, worrying, and anxious individuals. Neuropsychologia 61:197\u2013209","journal-title":"Neuropsychologia"}],"container-title":["Current Topics in Behavioral Neurosciences","Disruptive Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/7854_2021_279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T20:08:36Z","timestamp":1661458116000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/7854_2021_279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783031121838","9783031121845"],"references-count":33,"URL":"https:\/\/doi.org\/10.1007\/7854_2021_279","relation":{},"ISSN":["1866-3370","1866-3389"],"issn-type":[{"value":"1866-3370","type":"print"},{"value":"1866-3389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"17 November 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}